Table of Contents Author Guidelines Submit a Manuscript
Journal of Lipids
Volume 2017, Article ID 8236325, 7 pages
https://doi.org/10.1155/2017/8236325
Research Article

Apolipoproteins A-I, B, and C-III and Obesity in Young Adult Cherokee

1Center for American Indian Health Research, College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190, USA
2Section of Diabetes and Endocrinology, Department of Pediatrics, Harold Hamm Diabetes Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
3The Cherokee Nation, P.O. Box 948, Tahlequah, OK 74465, USA

Correspondence should be addressed to Piers Blackett; ten.tta@ttekcalbsreip

Received 8 February 2017; Accepted 20 March 2017; Published 3 April 2017

Academic Editor: Gerd Schmitz

Copyright © 2017 Wenyu Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. H. Eckel, W. W. Barouch, and A. G. Ershow, “Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases working group on the pathophysiology of obesity-associated cardiovascular disease,” Circulation, vol. 105, no. 24, pp. 2923–2928, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. B. V. Howard, E. T. Lee, L. D. Cowan et al., “Rising tide of cardiovascular disease in American Indians: The Strong Heart Study,” Circulation, vol. 99, no. 18, pp. 2389–2395, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Alaupovic, P. Blackett, W. Wang, and E. Lee, “Characterization of the metabolic syndrome by apolipoproteins in the Oklahoma Cherokee,” Journal of the Cardiometabolic Syndrome, vol. 3, no. 4, pp. 193–199, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. S. M. Haffner, M. P. Stern, H. P. Hazuda, B. D. Mitchell, and J. K. Patterson, “Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?” The Journal of the American Medical Association, vol. 263, no. 21, pp. 2893–2898, 1990. View at Publisher · View at Google Scholar · View at Scopus
  5. J. B. Meigs, P. W. Wilson, C. S. Fox et al., “Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease,” The Journal of Clinical Endocrinology & Metabolism, vol. 91, no. 8, pp. 2906–2912, 2006. View at Publisher · View at Google Scholar
  6. N. Stefan, H. U. Häring, F. B. Hu, and M. B. Schulze, “Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications,” The Lancet Diabetes & Endocrinology, vol. 1, no. 2, pp. 152–162, 2013. View at Publisher · View at Google Scholar
  7. J. Elovson, J. E. Chatterton, G. T. Bell et al., “Plasma very low density lipoproteins contain a single molecule of apolipoprotein B,” Journal of Lipid Research, vol. 29, no. 11, pp. 1461–1473, 1988. View at Google Scholar · View at Scopus
  8. A. D. Sniderman, “Applying apoB to the diagnosis and therapy of the atherogenic dyslipoproteinemias: a clinical diagnostic algorithm,” Current Opinion in Lipidology, vol. 15, no. 4, pp. 433–438, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. P. R. Blackett, K. S. Blevins, M. Stoddart et al., “Body mass index and high-density lipoproteins in Cherokee Indian children and adolescents,” Pediatric Research, vol. 58, no. 3, pp. 472–477, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Walldus, I. Jungner, A. H. Aastveit, I. Holme, C. D. Furberg, and A. D. Sniderman, “The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk,” Clinical Chemistry and Laboratory Medicine, vol. 42, no. 12, pp. 1355–1363, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Burstein and R. Morlin, “Precipitation of serum lipoproteins by anionic detergents in the presence of bivalent cations,” Revue Européenne D'études Cliniques et Biologiques, vol. 15, no. 1, pp. 109–113, 1970. View at Google Scholar
  12. W. Wang, S. Khan, P. Blackett, P. Alaupovic, and E. Lee, “Apolipoproteins A-I, B, and C-III in young adult Cherokee with metabolic syndrome with or without type 2 diabetes,” Journal of Clinical Lipidology, vol. 7, no. 1, pp. 38–42, 2013. View at Publisher · View at Google Scholar
  13. C. O. Mendivil, E. B. Rimm, J. Furtado, S. E. Chiuve, and F. M. Sacks, “Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease,” Circulation, vol. 124, no. 19, pp. 2065–2072, 2011. View at Publisher · View at Google Scholar
  14. F. M. Sacks, P. Alaupovic, L. A. Moye et al., “VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the cholesterol and recurrent events (CARE) trial,” Circulation, vol. 102, no. 16, pp. 1886–1892, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. D. H. Blankenhorn, R. H. Selzer, D. W. Crawford et al., “Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound,” Circulation, vol. 88, no. 1, pp. 20–28, 1993. View at Publisher · View at Google Scholar · View at Scopus
  16. M. K. Jensen, E. B. Rimm, J. D. Furtado, and F. M. Sacks, “Apolipoprotein C-III as a potential modulator of the association between HDL-cholesterol and incident coronary heart disease,” Journal of the American Heart Association, vol. 1, no. 2, Article ID e000232, 2012. View at Publisher · View at Google Scholar
  17. The TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute, “Loss-of-function mutations in APOC3, triglycerides, and coronary disease,” The New England Journal of Medicine, vol. 371, no. 1, pp. 22–31, 2014. View at Publisher · View at Google Scholar
  18. M. J. Graham, R. G. Lee, T. A. Bell III et al., “Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans,” Circulation Research, vol. 112, no. 11, pp. 1479–1490, 2013. View at Publisher · View at Google Scholar
  19. M. C. Wyler Von Ballmoos, B. Haring, and F. M. Sacks, “The risk of cardiovascular events with increased apolipoprotein CIII: a systematic review and meta-analysis,” Journal of Clinical Lipidology, vol. 9, no. 4, pp. 498–510, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. B. Talayero, L. Wang, J. Furtado, V. J. Carey, G. A. Bray, and F. M. Sacks, “Obesity favors apolipoprotein E- and C-III-containing high density lipoprotein subfractions associated with risk of heart disease,” Journal of Lipid Research, vol. 55, no. 10, pp. 2167–2177, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. M. D. Curry, W. J. McConathy, J. D. Fesmire, and P. Alaupovic, “Quantitative determination of human apolipoprotein Cc-III by electroimmunoassay,” Biochimica et Biophysica Acta (BBA)—Lipids and Lipid Metabolism, vol. 617, no. 3, pp. 503–513, 1980. View at Publisher · View at Google Scholar · View at Scopus
  22. M. D. Curry, P. Alaupovic, and C. A. Suenram, “Determination of apolipoprotein A and its constitutive A-I and A-II polypeptides by separate electroimmunoassays,” Clinical Chemistry, vol. 22, no. 3, pp. 315–322, 1976. View at Google Scholar · View at Scopus
  23. M. D. Curry, A. Gustafson, P. Alaupovic, and W. J. McConathy, “Electroimmunoassay, radioimmunoassay, and radial immunodiffusion assay evaluated for quantification of human apolipoprotein B,” Clinical Chemistry, vol. 24, no. 2, pp. 280–286, 1978. View at Google Scholar · View at Scopus
  24. D. Samocha-Bonet, D. Chisholm, K. Tonks, L. Campbell, and J. Greenfield, “Insulin-sensitive obesity in humans—a “favorable fat” phenotype?” Trends in Endocrinology & Metabolism, vol. 23, no. 3, pp. 116–124, 2012. View at Publisher · View at Google Scholar
  25. N. Kloting, M. Fasshauer, A. Dietrich et al., “Insulin-sensitive obesity,” American Journal of Physiology. Endocrinology and Metabolism, vol. 299, no. 3, pp. E506–E515, 2010. View at Publisher · View at Google Scholar
  26. N. Stefan, K. Kantartzis, J. Machann et al., “Identification and characterization of metabolically benign obesity in humans,” Archives of Internal Medicine, vol. 168, no. 15, pp. 1609–1616, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. Z. Cui, K. P. Truesdale, P. T. Bradshaw, J. Cai, and J. Stevens, “Three-year weight change and cardiometabolic risk factors in obese and normal weight adults who are metabolically healthy: the atherosclerosis risk in communities study,” International Journal of Obesity, vol. 39, no. 8, pp. 1203–1208, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Eisenberg, J. R. Patsch, J. T. Sparrow, A. M. Gotto, and T. Olivecrona, “Very low density lipoprotein. Removal of apolipoproteins C-II and C-III-1 during lipolysis in vitro,” The Journal of Biological Chemistry, vol. 254, no. 24, pp. 12603–12608, 1979. View at Google Scholar · View at Scopus
  29. K. Olin-Lewis, R. M. Krauss, M. La Belle et al., “ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan biglycan,” Journal of Lipid Research, vol. 43, no. 11, pp. 1969–1977, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Zheng, V. Azcutia, E. Aikawa et al., “Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion,” European Heart Journal, vol. 34, no. 8, pp. 615–624, 2013. View at Publisher · View at Google Scholar
  31. J. Altomonte, L. Cong, S. Harbaran et al., “Foxo1 mediates insulin action on apoC-III and triglyceride metabolism,” The Journal of Clinical Investigation, vol. 114, no. 10, pp. 1493–1503, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. P. R. Blackett, K. S. Blevins, E. Quintana et al., “ApoC-III bound to apoB-containing lipoproteins increase with insulin resistance in Cherokee Indian youth,” Metabolism: Clinical and Experimental, vol. 54, no. 2, pp. 180–187, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. V. Ceccarelli, G. Nocentini, C. Riccardi et al., “Effect of dietary saturated fatty acids on HNF-4α DNA binding activity and ApoCIII mRNA in sedentary rat liver,” Molecular and Cellular Biochemistry, vol. 347, no. 1-2, pp. 29–39, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. N. Faghihnia, L. M. Mangravite, S. Chiu, N. Bergeron, and R. M. Krauss, “Effects of dietary saturated fat on LDL subclasses and apolipoprotein CIII in men,” European Journal of Clinical Nutrition, vol. 66, no. 11, pp. 1229–1233, 2012. View at Publisher · View at Google Scholar
  35. S. Caron, A. Verrijken, I. Mertens et al., “Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 3, pp. 513–519, 2011. View at Publisher · View at Google Scholar
  36. B. V. Howard, G. Ruotolo, and D. C. Robbins, “Obesity and dyslipidemia,” Endocrinology and Metabolism Clinics of North America, vol. 32, no. 4, pp. 855–867, 2003. View at Publisher · View at Google Scholar
  37. N. Stefan, H. Häring, F. B. Hu, and M. B. Schulze, “Divergent associations of height with cardiometabolic disease and cancer: epidemiology, pathophysiology, and global implications,” The Lancet Diabetes & Endocrinology, vol. 4, no. 5, pp. 457–467, 2016. View at Publisher · View at Google Scholar
  38. G. F. Lewis and D. J. Rader, “New insights into the regulation of HDL metabolism and reverse cholesterol transport,” Circulation Research, vol. 96, no. 12, pp. 1221–1232, 2005. View at Publisher · View at Google Scholar
  39. N. Stefan, A. Fritsche, F. Schick, and H. Häring, “Phenotypes of prediabetes and stratification of cardiometabolic risk,” The Lancet Diabetes & Endocrinology, vol. 4, no. 9, pp. 789–798, 2016. View at Publisher · View at Google Scholar
  40. C. M. Phillips, C. Dillon, J. M. Harrington et al., “Defining metabolically healthy obesity: role of dietary and lifestyle factors,” PLoS ONE, vol. 8, no. 10, Article ID e76188, 2013. View at Publisher · View at Google Scholar
  41. S. Velho, F. Paccaud, G. Waeber, P. Vollenweider, and P. Marques-Vidal, “Metabolically healthy obesity: different prevalences using different criteria,” European Journal of Clinical Nutrition, vol. 64, no. 10, pp. 1043–1051, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. N. E. Miller, D. S. Thelle, O. H. Forde, and O. D. Mjos, “The Tromso heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study,” The Lancet, vol. 1, no. 8019, pp. 965–968, 1977. View at Google Scholar
  43. P. Barter, A. M. Gotto, J. C. LaRosa et al., “HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events,” The New England Journal of Medicine, vol. 357, no. 13, pp. 1301–1310, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. B. Vergès, M. Adiels, J. Boren et al., “Interrelationships between the kinetics of VLDL subspecies and hdl catabolism in abdominal obesity: a multicenter tracer kinetic study,” Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 11, pp. 4281–4290, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. G. Walldius, I. Jungner, I. Holme, A. H. Aastveit, W. Kolar, and E. Steiner, “High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study,” The Lancet, vol. 358, no. 9298, pp. 2026–2033, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. W. A. Van Der Steeg, S. M. Boekholdt, E. A. Stein et al., “Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk,” Annals of Internal Medicine, vol. 146, no. 9, pp. 640–648, 2007. View at Publisher · View at Google Scholar · View at Scopus